Psoriatic Arthritis Observational Study of Persistence of Treatment (PRO-SPIRIT Study)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/31175
• EU PAS number:
  EUPAS31174
• Study ID:
  31175
• Official title and acronym:
  Psoriatic Arthritis Observational Study of Persistence of Treatment (PRO-SPIRIT Study)
• DARWIN EU® study:
  No
• Study countries:
  Canada

  France

  Germany

  Italy

  Spain

  United Kingdom
• Study description:
  The present observational study is to describe the 24-month persistence alongside effectiveness and healthcare resource use associated with bDMARD and tsDMARD treatments for PsA.
• Study status:
  Planned

Research institutions and networks

Institutions

Syneos Health

United Kingdom

Study timelines

Date when funding contract was signed

Planned: 01/06/2019

Study start date

Planned: 31/10/2019

Date of final study report

Planned: 31/10/2023

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Eli Lilly & Company

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable